Alexandria Real Estate Equities (ARE)
(Delayed Data from NYSE)
$124.41 USD
+2.23 (1.83%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $124.42 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$124.41 USD
+2.23 (1.83%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $124.42 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Zacks News
Alexandria (ARE) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Alexandria's (ARE) Q4 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high-interest expenses and economic uncertainty raise concern.
Seeking Clues to Alexandria Real Estate Equities (ARE) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Alexandria Real Estate Equities (ARE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Here's Why You Should Retain Alexandria (ARE) Stock for Now
by Zacks Equity Research
Alexandria (ARE) is likely to benefit from the solid demand for top-quality life-science assets in key markets. However, a vast development outlay amid high interest rates is concerning.
Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand
by Zacks Equity Research
Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses in Greater Boston and San Carlos in the San Francisco Bay Area.
Alexandria Real Estate Equities (ARE) Stock Jumps 7.1%: Will It Continue to Soar?
by Zacks Equity Research
Alexandria Real Estate Equities (ARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights Prologis, Alexandria Real Estate Equities, The Macerich and Innovative Industrial Properties
by Zacks Equity Research
Prologis, Alexandria Real Estate Equities, The Macerich and Innovative Industrial Properties are part of the Zacks top Analyst Blog.
REITs Rejoice as the Fed Indicates Three Rate Cuts in 2024
by Moumita C. Chattopadhyay
The latest decision of the Fed to hold its benchmark rate steady and the indications of three rate cuts next year should give REIT investors enough reason to rejoice.
Is Mid-America's (MAA) Latest Dividend Hike Sustainable?
by Zacks Equity Research
Mid-America's (MAA) recent dividend hike of 5% is likely to be sustainable, given the company's operational and financial strength.
Should You Retain Alexandria (ARE) Stock in Your Portfolio Now?
by Zacks Equity Research
High demand for Alexandria's (ARE) top-quality life science assets bodes well. Yet, a vast development outlay exposes it to the risk of rising construction costs amid high-interest rates.
Focus on These 5 Stocks That Recently Hiked Dividends
by Zacks Equity Research
Investors may keep a tab on stocks like ARE, SUZ, GGG, COFS and LZB, which have lately hiked their dividend payments.
Alexandria (ARE) Rewards Investors, Hikes Dividend by 2.4%
by Zacks Equity Research
Alexandria (ARE) boosts investors' confidence with a dividend hike of 2.4%. Robust operating results, a decent financial position and a lower payout ratio make the dividend rate sustainable.
Alexandria (ARE) Rises 12% in a Month: Will the Trend Last?
by Zacks Equity Research
Robust demand for top-quality life-science assets in key markets is likely to drive Alexandria's (ARE) performance. However, a vast development outlay exposes it to the risk of rising construction costs.
Alexandria (ARE), Eli Lilly to Expand Gateway Labs to San Diego
by Zacks Equity Research
The expansion of Gateway Labs to San Diego reaffirms the strength and depth of the partnership between Alexandria (ARE) and Eli Lilly.
Boston Properties (BXP) Q3 FFO & Revenues Top, '23 View Revised
by Zacks Equity Research
Boston Properties' (BXP) Q3 results outshine estimates on better-than-anticipated revenues, aided by healthy leasing activity. The company revises its 2023 guidance for FFO per share.
Is a Beat in the Offing for Ventas (VTR) in Q3 Earnings?
by Zacks Equity Research
Favorable senior housing operating portfolio operating trends, robust demand for life-science real-estate assets and accretive investments are likely to have benefited Ventas' (VTR) Q3 earnings.
Welltower (WELL) Q3 FFO Tops, SHO Occupancy Up, '23 View Raised
by Zacks Equity Research
Welltower's (WELL) Q3 earnings outshine estimates on better-than-anticipated revenues. The SHO portfolio occupancy improves year over year. The company raises its 2023 FFO per share outlook.
Healthpeak's (PEAK) Q3 FFO & Revenues Top, '23 View Raised
by Zacks Equity Research
Healthpeak's (PEAK) posts stellar Q3 results on better-than-expected revenues. Same-store portfolio cash (adjusted) net operating income rises across the portfolio. It also raises the 2023 outlook.
Cousins Properties (CUZ) Q3 FFO Meets Mark, '23 View Revised
by Zacks Equity Research
Cousins Properties' (CUZ) Q3 results reflect decent leasing activity. However, a jump in interest expenses acts as a dampener. It revises the outlook for 2023 FFO per share.
American Tower's (AMT) Q3 AFFO & Revenues Top, '23 View Raised
by Zacks Equity Research
American Tower's (AMT) posts stellar Q3 results on better-than-anticipated revenues and solid organic tenant billings growth. It also raises the outlook for 2023.
Equinix's (EQIX) Q3 AFFO Beats, Dividend Hiked, '23 View Up
by Zacks Equity Research
Equinix (EQIX) posts stellar Q3 results backed by strong demand for its colocation and interconnection services. It hikes its dividend payout by 25% and raises AFFO per share guidance for 2023.
Alexandria's (ARE) Q3 AFFO Tops on Rent Growth, '23 View Revised
by Zacks Equity Research
Alexandria Real Estate's (ARE) Q3 results reflect year-over-year growth in revenues on decent leasing activity and solid rental rate growth. It raises the midpoint of its 2023 AFFO per share outlook.
Alexandria Real Estate Equities (ARE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Alexandria Real Estate Equities (ARE) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alexandria Real Estate Equities (ARE) Q3 FFO Top Estimates
by Zacks Equity Research
Alexandria Real Estate Equities (ARE) delivered FFO and revenue surprises of 0.89% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Alexandria (ARE) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Alexandria's (ARE) Q3 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high-interest expenses and economic uncertainty raise concern.
Alexandria (ARE) Receives Rating Affirmation From Moody's
by Zacks Equity Research
Underpinning Alexandria's (ARE) solid operating and financial performance, Moody's Investors Service reaffirms the company's credit ratings of Baa1 and maintains its outlook rating at stable.